SC rejects plea of Axis Bank against release of arbitral award money to Japanese firm Daiichi

Image
Press Trust of India New Delhi
Last Updated : Dec 13 2018 | 8:10 PM IST

The Supreme Court Thursday refused to entertain an Axis Bank plea opposing the release of Rs 9.39 crore, which is part of Rs 3,500 crore awarded by a Singapore tribunal to Daiichi Sankyo in its case against former Ranbaxy promoters Malvinder and Shivinder Singh.

Axis Bank, which lent money to Ranbaxy and has secured an order for attachment of properties from the Debt Recovery Tribunal (DRT), had recently moved the Delhi High Court saying that the Japanese pharma major not be allowed to realise the part payment of the award "unless a proportionate amount of money is kept back" for it.

The high court, which is hearing a plea of Daiichi seeking execution of the Rs 3,500 crore Singapore tribunal arbitral award against former Ranbaxy promoters, had rejected the plea of Axis Bank. The private bank challenged it in the apex court.

Senior advocate Ranjit Kumar, appearing for Axis Bank, told a bench headed by Chief Justice Ranjan Gogoi that the lending bank was armed with an attachment order from the DRT in its favour and if the Japanese firm is allowed to realise the entire arbitral award sum, then nothing would remain for it.

"Heard the counsel for the petitioner and perused the relevant material...We are not inclined to interfere. The Special Leave Petition is accordingly dismissed," said the bench, also comprising justices S K Kaul and K M Joseph.

Daiichi had bought Ranbaxy in 2008. Later, it had moved the Singapore arbitration tribunal accusing that the Singh brothers had concealed information that the Indian company was facing probe by the US Food and Drug Administration and the Department of Justice, while selling its shares.

Daiichi had to enter into a settlement agreement with the US Department of Justice, agreeing to pay USD 500 million penalty to resolve potential, civil and criminal liability. The company had then sold its stake in Ranbaxy to Sun Pharmaceuticals for Rs 22,679 crore in 2015.

Earlier, the High Court, while hearing the plea of the Japnese firm for execution of arbitral award, had asked Malvinder and Shivinder Singh to maintain status quo with regard to their assets, disclosed by them during the arbitral proceedings,

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 13 2018 | 8:10 PM IST

Next Story